<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="106198">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01721876</url>
  </required_header>
  <id_info>
    <org_study_id>1230.14</org_study_id>
    <secondary_id>2012-002487-27</secondary_id>
    <nct_id>NCT01721876</nct_id>
  </id_info>
  <brief_title>Volasertib in Combination With Low-dose Cytarabine in Patients Aged 65 Years and Above With Previously Untreated Acute Myeloid Leukaemia, Who Are Ineligible for Intensive Remission Induction Therapy (POLO-AML-2)</brief_title>
  <official_title>A Phase III Randomised, Double-blind, Controlled, Parallel Group Study of Intravenous Volasertib in Combination With Subcutaneous Low-dose Cytarabine vs. Placebo + Low-dose Cytarabine in Patients &gt;=65 Years With Previously Untreated Acute Myeloid Leukaemia, Who Are Ineligible for Intensive Remission Induction Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      To investigate the efficacy, safety, and pharmacokinetics of intravenous volasertib +
      subcutaneous low dose cytarabine in patients &gt;= 65 years of age with previously untreated
      acute myeloid leukaemia, ineligible for intensive remission induction therapy
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">February 2017</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double-Blind</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete Remission (CR)</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Complete remission with incomplete blood count recovery (CRi)</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free survival (EFS)</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse-free survival (RFS)</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">666</enrollment>
  <condition>Leukemia, Myeloid, Acute</condition>
  <arm_group>
    <arm_group_label>Volasertib + low dose cytarabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PLACEBO + low dose cytarabine</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>comparator</description>
    <arm_group_label>PLACEBO + low dose cytarabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>volasertib</intervention_name>
    <description>'Investigational Medicinal Product</description>
    <arm_group_label>Volasertib + low dose cytarabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>low dose cytarabine</intervention_name>
    <description>background medication</description>
    <arm_group_label>PLACEBO + low dose cytarabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>low dose cytarabine</intervention_name>
    <description>background medication</description>
    <arm_group_label>Volasertib + low dose cytarabine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Age &gt;= 65years.

          2. Cytologically/histologically confirmed acute myeloid leukaemia (AML) according to WHO
             classification; (except for acute promyelocytic leukaemia (APL).

          3. Previously untreated AML (except for hydroxyurea and/or corticosteroid therapy for no
             more than 28 days (cumulative)). Previous therapy for Myelodysplastic Syndrome (MDS)
             is allowed.

          4. Investigator considers patient ineligible for intensive remission induction therapy
             based on documented medical reasons (e.g. disease characteristics like AML genetics,
             type of AML (de novo or secondary), and patient characteristics like performance
             score, concomitant diagnoses, organ dysfunctions).

          5. Patient is eligible for Low-Dose Cytarabine (LDAC) treatment.

          6. Eastern co-operative oncology group (ECOG) performance score &lt;= 2 at screening.

          7. Signed and dated written informed consent by start date of Screening visit in
             accordance with Good Clinical Practice (GCP) and local legislation.

        Exclusion criteria:

          1. Prior or concomitant chemotherapy for AML (with the exception of hydroxyurea and/or
             corticosteroid therapy for no more than 28 days (cumulative)). Please note that any
             prior therapy for MDS is allowed.

          2. Treatment with any investigational drug within 2 weeks before first administration of
             present trial drug.

          3. Acute promyelocytic leukaemia (French-American-British (FAB) classification subtype
             M3).

          4. Current clinical central nervous system (CNS) symptoms deemed by the investigator to
             be related to leukaemic CNS involvement (no lumbar puncture required, clinical
             assessment per investigator´s judgement is sufficient).

          5. Hypersensitivity to one of the trial drugs or the excipients.

          6. Severe illness or organ dysfunction involving the heart, kidney, liver or other organ
             system (e.g. active infection, clinically relevant impairment of cardiac function,
             severe heart failure/cardiac insufficiency, unstable angina pectoris or history of
             recent myocardial infarction), which in the opinion of the investigator precludes
             treatment with LDAC.

          7. Corrected QT interval according to Fridericia (QTcF) prolongation &gt; 470 ms or QT
             prolongation deemed clinically relevant by the investigator (e.g., congenital long QT
             syndrome).The QTcF will be calculated as the mean of the 3 Electrocardiogram (ECGs)
             taken at screening.

          8. Total bilirubin &gt; 3 x upper limit of normal (ULN).

          9. Creatinine clearance (CLcr) &lt; 30 ml/min (estimated creatinine clearance by the
             Cockcroft-Gault (C-G) equation) .

         10. Active hepatitis B or hepatitis C, or laboratory evidence for a chronic infection.

         11. HIV infection.

         12. Second malignancy currently requiring active therapy (except for
             hormonal/anti-hormonal treatment e.g. in prostate or breast cancer).

         13. Any significant concurrent psychiatric disorder or social situation that according to
             the investigator´s judgement would compromise patient´s safety or compliance,
             interfere with consent, study participation, or interpretation of study results.

         14. Known or suspected active alcohol or drug abuse.

         15. Patient unable to comply with the protocol, in the opinion of the investigator.

         16. Male patients with partners of childbearing potential who are unwilling to use
             condoms in combination with a second medically acceptable method of contraception
             during the trial and for a minimum of 6 months after study treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1230.14.10012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.10006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Duluth</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.10015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.10001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.54002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mendoza</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.54005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Miguel de Tucumán</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.43001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.43003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Leoben</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.43002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.32002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Brugge</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.32001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.32007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Haine-Saint-Paul</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.32003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hasselt</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.32005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.32006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Liège</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.32008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Roeselare</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.32004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Yvoir</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.55003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jau</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.55001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Porto Alegre</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.55002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ribeirao Preto</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.11005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.11004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.11001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.11002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.11003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.42004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hradec Kralove</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.42003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Plzen - Lochotin</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.42002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Praha 10</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.35801 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.35802 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Turku</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.33011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Amiens Cedex 1</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.33003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Angers Cedex 09</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.33012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.33002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>La Tronche</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.33001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Le Chesnay cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.33007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Limoges Cedex 1</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.33008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Marseille Cedex 09</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.33015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.33004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Paris Cedex 12</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.33005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pessac cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.33006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pierre Bénite Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.33013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rennes Cedex 9</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.33014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toulouse Cedex 9</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.49012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Augsburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.49005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.49022 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Braunschweig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.49015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Erlangen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.49010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.49003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Frankfurt/Main</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.49020 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Göttingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.49023 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Halle (Saale)</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.49007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.49008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.49004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.49006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.49021 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.49018 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Marburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.49009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.49002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.49016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Regensburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.49014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Stuttgart</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.49001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ulm</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.49011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Villingen-Schwenningen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.30001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.30005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.30004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ioannina</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.30002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Patras</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.30003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Thessaloniki</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.36002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.36003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gyor</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.36001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Szeged</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.91003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bangalore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.91001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mumbai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.39004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Brescia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.39001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.39003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.81006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aichi, Nagoya</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.81016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aichi, Nagoya</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.81014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Akita, Akita</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.81005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fukui, Yoshida-gun</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.81007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fukuoka, Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.81013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hyogo, Kobe</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.81010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kanagawa, Isehara</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.81011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kanagawa, Yokohama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.81001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Miyagi, Sendai</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.81008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nagasaki, Nagasaki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.81018 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Okayama, Kurashiki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.81012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Okayama, Okayama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.81009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Osaka, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.81003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tokyo, Chuo-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.81004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tokyo, Sinagawa-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.82006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hwasun</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.82001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.82002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.82003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.82004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.82005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.52001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Monterrey</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.31001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.47001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bergen</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.47003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Grålum</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.48001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lodz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.48003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Torun</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.35003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lisboa</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.35001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Porto</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.35004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Porto</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.35005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Porto</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.07007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Irkutsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.07002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.07004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nizhniy Novgorod</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.07006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.27003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moreleta Park, Pretoria</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.34003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Badalona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.34001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.34004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.34008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.34005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.34006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.34007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Salamanca</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.34002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.88603 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>ChangHua</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.88601 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.14.88602 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Malaysia</country>
    <country>Thailand</country>
  </removed_countries>
  <verification_date>August 2016</verification_date>
  <lastchanged_date>August 22, 2016</lastchanged_date>
  <firstreceived_date>November 2, 2012</firstreceived_date>
  <firstreceived_results_disposition_date>October 14, 2014</firstreceived_results_disposition_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cytarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted -->
</clinical_study>
